169 related articles for article (PubMed ID: 8908287)
1. Chemotherapy and granulocyte-colony stimulating factor for non-Hodgkin's lymphoma of the head and neck.
Tsuge I; Suzuki K; Moribe K; Motai H; Kimura T; Umeda K; Kobayashi T; Yokota A; Hondo J; Baba S
Acta Otolaryngol Suppl; 1996; 525():129-34. PubMed ID: 8908287
[TBL] [Abstract][Full Text] [Related]
2. Mobilization of peripheral blood stem cells by granulocyte-colony stimulating factors: comparison of a standard dose of glycosylated and mutated granulocyte-colony stimulating factor in non-Hodgkin's lymphoma patients following CHOP therapy.
Takemoto Y; Wada H; Takatsuka H; Okamoto T; Kakishita E
Drugs Exp Clin Res; 2000; 26(1):1-5. PubMed ID: 10761530
[TBL] [Abstract][Full Text] [Related]
3. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
[TBL] [Abstract][Full Text] [Related]
4. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
5. [Clinical study of recombinant human granulocyte colony stimulating factor (rhG-CSF) on leukopenia induced by chemotherapy in cancer patients].
Shi YK; Zhou JC; Feng FY
Zhonghua Zhong Liu Za Zhi; 1994 May; 16(3):207-10. PubMed ID: 7525173
[TBL] [Abstract][Full Text] [Related]
6. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
[TBL] [Abstract][Full Text] [Related]
7. Use of granulocyte colony-stimulating factor (G-CSF) and outcome in patients with non-chemotherapy agranulocytosis.
Ibáñez L; Sabaté M; Ballarín E; Puig R; Vidal X; Laporte JR;
Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):224-8. PubMed ID: 18181220
[TBL] [Abstract][Full Text] [Related]
8. Effects of recombinant granulocyte colony-stimulating factor (G-CSF) in patients treated with ProMACE-CytaBOM for HIV-related non-Hodgkin's lymphoma (NHL).
Rossi G; Donisi A; Casari S; Re A; Stellini R; Cadeo G; Carosi G
Haematologica; 1998 Apr; 83(4):317-22. PubMed ID: 9592981
[TBL] [Abstract][Full Text] [Related]
9. The neutrophil, not the tumor: serum CA 15-3 elevation as a result of granulocyte--colony-stimulating factor-induced neutrophil MU1C overexpression and neutrophilia in patients with breast carcinoma receiving adjuvant chemotherapy.
Pentheroudakis G; Malamou-Mitsi V; Briasoulis E; Damala K; Vassou A; Vartholomatos G; Kolaitis N; Pavlidis N
Cancer; 2004 Oct; 101(8):1767-75. PubMed ID: 15386335
[TBL] [Abstract][Full Text] [Related]
10. Naturally occurring and therapy-induced antibodies to human granulocyte colony-stimulating factor (G-CSF) in human serum.
Laricchia-Robbio L; Moscato S; Genua A; Liberati AM; Revoltella RP
J Cell Physiol; 1997 Nov; 173(2):219-26. PubMed ID: 9365526
[TBL] [Abstract][Full Text] [Related]
11. G-CSF during large field radiotherapy reduces bone marrow recovery capacity.
Pape H; Orth K; Heese A; Heyll A; Kobbe G; Schmitt G; Niederbichler AD; Peiper M; Schwarz A; Boelke E
Eur J Med Res; 2006 Aug; 11(8):322-8. PubMed ID: 17052967
[TBL] [Abstract][Full Text] [Related]
12. Biological and clinical correlates after chemotherapy and granulocyte colony-stimulating factor administration.
Higa GM; DeVore RF; Auber ML; Lynch JP; Landreth KS
Pharmacotherapy; 1998; 18(1):1-8. PubMed ID: 9469674
[TBL] [Abstract][Full Text] [Related]
13. Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma.
Hashino S; Morioka M; Irie T; Shiroshita N; Kawamura T; Suzuki S; Iwasaki H; Umehara S; Kakinoki Y; Kurosawa M; Kahata K; Izumiyama K; Kobayashi H; Onozawa M; Takahata M; Fujisawa F; Kondo T; Asaka M
Int J Lab Hematol; 2008 Aug; 30(4):292-9. PubMed ID: 18665826
[TBL] [Abstract][Full Text] [Related]
14. Neutropenic complications in advanced-stage non-Hodgkin's lymphoma: implications for the use of prophylactic recombinant human granulocyte-colony stimulating factor (G-CSF).
Bobey N; Woodman RC
Clin Invest Med; 1998 Apr; 21(2):63-70. PubMed ID: 9562926
[TBL] [Abstract][Full Text] [Related]
15. [G-CSF in practice: malignant non-Hodgkin's lymphomas].
Rossi JF
Pathol Biol (Paris); 1993 Jan; 41(1):44-5. PubMed ID: 7686283
[No Abstract] [Full Text] [Related]
16. fMLP-induced CD11b/CD18 upregulation on neutrophils from patients with non-Hodgkin's lymphomas treated with recombinant human granulocyte colony-stimulating factor.
Carulli G; Azzarà A; Minnucci S; Angiolini C; Sbrana S; Ambrogi F
J Exp Clin Cancer Res; 1997 Sep; 16(3):301-8. PubMed ID: 9387905
[TBL] [Abstract][Full Text] [Related]
17. CD64 surface expression on neutrophils and monocytes is significantly up-regulated after stimulation with granulocyte colony-stimulating factor during CHOP chemotherapy for patients with non-Hodgkin's lymphoma.
Kakinoki Y; Kubota H; Yamamoto Y
Int J Hematol; 2004 Jan; 79(1):55-62. PubMed ID: 14979480
[TBL] [Abstract][Full Text] [Related]
18. 4-Hydroperoxycyclophosphamide purged autologous bone marrow transplantation of relapsed, responding non-Hodgkin's lymphoma with granulocyte colony stimulating factor support results in reliable hematopoietic recovery.
Biggs D; Stadtmauer E; Mangan P; Edelstein M; Powlis W; Buzby G; Magee D; Sachs B; Silberstein L
Prog Clin Biol Res; 1994; 389():9-15. PubMed ID: 7535466
[No Abstract] [Full Text] [Related]
19. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
Aurlien E; Holte H; Pharo A; Kvaløy S; Jakobsen E; Smeland EB; Kvalheim G
Bone Marrow Transplant; 1998 May; 21(9):873-8. PubMed ID: 9613778
[TBL] [Abstract][Full Text] [Related]
20. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
